Payors are crucial in the adoption of new medicines, especially in markets that prioritise cost-effectiveness.
While HTA agencies and payors often prioritise clinical trial data, there are significant evidence gaps that these trials do not cover. Real-World Evidence (RWE) becomes crucial in this scenario, offering additional context and data to support reimbursement applications.
Submitting incomplete or inadequate RWE alongside Randomised Clinical Trial Evidence (RCTE) can severely impact the reimbursement process. Relying on assumptions not only increases uncertainty but also reduces the accuracy of the data presented, ultimately decreasing the chances of successful reimbursement.
To address these challenges, it is essential to enhance the impact of RWE in meeting the specific concerns of payors. By doing so, we can reduce dependence on potentially flawed assumptions and accelerate patient access to new medications.
Creating a comprehensive list of disease costs using the Jandhyala Method ensures all relevant expenses are considered, including direct medical and non-medical costs, indirect costs, and even those difficult to measure, offering a more complete picture than clinical trials alone.
At Medialis Ltd, we specialise in developing robust RWE strategies that complement RCTE, filling crucial evidence gaps and facilitating smoother reimbursement negotiations. Connect with us to learn how our expertise can streamline your product’s path to market.
#RealWorldEvidence #RWE #MarketAccess #MedicalAffairs #Payor
Link: https://www.linkedin.com/feed/update/urn:li:share:7224394881517969408/?actorCompanyId=11809093